2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 7,604
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Osamu Okuda | President, CEO & Representative Director | 1.38M | N/A | 1963 |
Mr. Toshiaki Itagaki | Head of Finance Supervisory Division, CFO & Executive VP | N/A | N/A | 1960 |
Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | N/A | N/A | N/A |
Mr. Shinji Hidaka | Executive VP and Head of Marketing & Sales Division | N/A | N/A | N/A |
Mr. Junichi Ebihara | Executive Vice President | N/A | N/A | N/A |
Dr. Yoshiaki Ohashi | SVP & Full-time Audit Supervisory Board Member | N/A | N/A | 1960 |
Mr. Tetsuya Yamaguchi | Executive VP and Head of Project, Lifecycle Management & Foundation Medicine Unit | N/A | N/A | N/A |
Mr. Yoshiyuki Yano | Executive Vice President | N/A | N/A | N/A |
Ms. Satoko Shisai | Executive VP & Head of Digital Transformation Unit | N/A | N/A | 1963 |
Dr. Shigehiro Yamada Ph.D. | Head of Sustainability Department and Full-Time Audit & Supervisory Board Member | N/A | N/A | 1964 |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 29 April 2024 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 1.